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Abstract: PURPOSE The classification of the International Germ-Cell Cancer Collaborative Group
(IGCCCG) has been a major advance in the management of germ-cell tumors, but relies on data of
only 660 patients with seminoma treated between 1975 and 1990. We re-evaluated this classification in
a database from a large international consortium. MATERIALS AND METHODS Data on 2,451 men
with metastatic seminoma treated with cisplatin- and etoposide-based first-line chemotherapy between
1990 and 2013 were collected from 30 institutions or collaborative groups in Australia, Europe, and North
America. Clinical trial and registry data were included. Primary end points were progression-free survival
(PFS) and overall survival (OS) calculated from day 1 of treatment. Variables at initial presentation
were evaluated for their prognostic impact. Results were validated in an independent validation set of
764 additional patients. RESULTS Compared with the initial IGCCCG classification, in our modern
series, 5-year PFS improved from 82% to 89% (95% CI, 87 to 90) and 5-year OS from 86% to 95% (95%
CI, 94 to 96) in good prognosis, and from 67% to 79% (95% CI, 70 to 85) and 72% to 88% (95% CI,
80 to 93) in intermediate prognosis patients. Lactate dehydrogenase (LDH) proved to be an additional
adverse prognostic factor. Good prognosis patients with LDH above 2.5× upper limit of normal had a
3-year PFS of 80% (95% CI, 75 to 84) and a 3-year OS of 92% (95% CI, 88 to 95) versus 92% (95% CI,
90 to 94) and 97% (95% CI, 96 to 98) in the group with lower LDH. CONCLUSION PFS and OS in
metastatic seminoma significantly improved in our modern series compared with the original data. The
original IGCCCG classification retains its relevance, but can be further refined by adding LDH at a cutoff
of 2.5× upper limit of normal as an additional adverse prognostic factor.
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Jörg Beyer, MD1; Laurence Collette, PhD2; Nicolas Sauvé, MSc2; Gedske Daugaard, MD3; Darren R. Feldman, MD4,5;
Torgrim Tandstad, MD6; Alexey Tryakin, MD7,8; Olof Stahl, MD9; Enrique Gonzalez-Billalabeitia, MD10,11; Ugo De Giorgi, MD12;
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ab
stract
PURPOSE The classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has been a major
advance in the management of germ-cell tumors, but relies on data of only 660 patients with seminoma treated
between 1975 and 1990. We re-evaluated this classification in a database from a large international consortium.
MATERIALS AND METHODSData on 2,451menwithmetastatic seminoma treatedwith cisplatin- and etoposide-based
first-line chemotherapy between1990 and2013were collected from30 institutions or collaborative groups in Australia,
Europe, and North America. Clinical trial and registry data were included. Primary end points were progression-free
survival (PFS) and overall survival (OS) calculated from day 1 of treatment. Variables at initial presentation were
evaluated for their prognostic impact. Results were validated in an independent validation set of 764 additional patients.
RESULTS Compared with the initial IGCCCG classification, in our modern series, 5-year PFS improved from 82%
to 89% (95% CI, 87 to 90) and 5-year OS from 86% to 95% (95% CI, 94 to 96) in good prognosis, and from 67%
to 79% (95% CI, 70 to 85) and 72% to 88% (95% CI, 80 to 93) in intermediate prognosis patients. Lactate
dehydrogenase (LDH) proved to be an additional adverse prognostic factor. Good prognosis patients with LDH
above 2.53 upper limit of normal had a 3-year PFS of 80% (95% CI, 75 to 84) and a 3-year OS of 92% (95% CI,
88 to 95) versus 92% (95% CI, 90 to 94) and 97% (95% CI, 96 to 98) in the group with lower LDH.
CONCLUSION PFS and OS in metastatic seminoma significantly improved in our modern series compared with
the original data. The original IGCCCG classification retains its relevance, but can be further refined by adding
LDH at a cutoff of 2.53 upper limit of normal as an additional adverse prognostic factor.
J Clin Oncol 00. © 2021 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
About one third of patients with seminoma present with
metastatic disease. In 1997, the International Germ-Cell
Cancer Collaborative Group (IGCCCG) published a
classification, which became the accepted international
standard and replaced all previous ones.1
However, the relevance of the original IGCCCG clas-
sification has been challenged. According to the
original IGCCCG classification, metastatic seminomas
are split into good or intermediate prognosis categories
based on the presence or absence of liver, bone, or
brain metastases.1 However, as data from only 660
patients with seminoma had been analyzed, the ability
to assess the impact of other relevant variables such as
age, lactate dehydrogenase (LDH), elevated human
chorionic gonadotropin (HCG) levels, or the presence
of pulmonary metastases was limited. Moreover, pa-
tients with seminoma included in the original IGCCCG
analysis were treated between 1975 and 1990 and
many had not received cisplatin or etoposide, which
would be the treatment backbone for metastatic
seminoma today.2,3
The IGCCCG-Update Consortium collected data on
metastatic seminoma with two major goals. First, to
validate the original IGCCCG criteria and update survival
probabilities in a modern cohort. Second, to explore
additional prognostic factors that may add granularity to
the original IGCCCG prognostic groups and explain
some of the heterogeneity found within the prognostic
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MATERIALS AND METHODS
The IGCCCG-Update Consortium
At the time of the first data collection, the IGCCCG-Update
Consortium consisted of 30 institutions or collaborative
groups in Australia, Europe, and North America. Potential
contributors were identified through contact between
peers, supplemented by a PubMed search. The principal
investigators of individual trials were invited to partici-
pate in the initiative based on a written data sharing
agreement.
In addition, the coordinators of national cooperative groups
in germ-cell tumor (GCT) or principal physicians at large
cancer centers were contacted in respect to the availability
of national or local cancer registries in electronic format.
Investigators were asked to contribute consecutive pa-
tients. The Protocol, the contributing centers/groups to the
IGCCCG Update Consortium, and the list of collected data
items are available in the Data Supplement, online only.
Data Collection
The purpose of the collaboration was to establish a common
electronic database with data of patients withmetastatic GCT
treated between 1990 and 2013—the IGCCCG-Update Data
Warehouse. To ensure appropriate representation of pa-
tients, and because trials often limit eligibility to specific
IGCCCG prognostic groups, structured data from national
registries, databases, or large cohorts of single-center data
on consecutively treated patients who fulfilled the protocol
data and eligibility requirements were collected in addition to
data from clinical trials.
After signing of the data sharing agreements, patient-level
data were aggregated, normalized, and harmonized. Data
were processed centrally and stored in a secure format at
the headquarters of the European Organisation of Research
and Treatment of Cancer in Brussels, Belgium.
Patient and Data
Thirty participating members of the IGCCCG consortium
located in Australia, Europe, and North America provided
anonymized, retrospective data on adult male patients with
metastatic pure seminoma or retroperitoneal or mediastinal
seminoma also when not metastatic.
All patients with seminoma had to receive minimum three
cycles of cisplatin- and etoposide-based conventional-dose
first-line treatment. Patients who received less than three
cycles were also eligible, provided there was enough evi-
dence that at least three cycles were intended. Patients with
elevated alpha-fetoprotein level (. 30 ng/mL), with prior
chemotherapy for metastatic disease, those included in the
original IGCCCG analysis published in 1997 as well as
patients with primary GCT of the brain were ineligible. The
treatment intended to be given to the patients was recorded
where available, otherwise treatments actually given were
used.
Data items included the original IGCCCG group, age, date of
metastatic diagnosis, primary site, levels of serum alpha-
fetoprotein, HCG, and LDH at diagnosis and before che-
motherapy as well as the presence and location of me-
tastases. Type and number of chemotherapy cycles were
obtained and progression status, vital status, cause of
death, and disease status at last follow-up were recorded.
Trials and Cohorts
We asked for electronic databases of studies and cohorts
comprising a minimum of 100 eligible patients for inclusion
in the warehouse. Only databases of first-line chemother-
apy as described in the patient eligibility criteria were in-
cluded. Retrospective data of first-line treatments of
patients who were primarily referred for relapse were not
included because it would have artificially inflated the
progression probabilities in the data warehouse.
CONTEXT
Key Objective
To reassess the original International Germ-Cell Cancer Collaborative Group (IGCCCG) classification for seminoma with
modern treatment data and to screen for additional prognostic variables.
Knowledge Generated
Even if applied to modern-type treatments, the IGCCCG classification still separates good prognosis from intermediate
prognosis seminoma and retains its relevance for clinical practice. However, survival probabilities have significantly
improved in both prognostic groups compared with the original publication from 1997. Lactate dehydrogenase at a cutoff
2.5x the upper limit of normal is identified as a new adverse prognostic variable among otherwise good prognosis patients.
Additional variables such as age, extragonadal primary tumor location, human chorionic gonadotropin levels, or the
presence of lung metastases were of minor relevance.
Relevance
The results of the IGCCCG update analysis help to counsel patients with seminoma more accurately in respect to the
treatment outcome they can expect and help to shape future trials in seminoma.
2 © 2021 by American Society of Clinical Oncology
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Independent Validation
In March 2019, an independent set of patients was collected
to validate the prognostic classification. This set consisted of
additional patients from the institutions contributing to the
analysis set, as well as patients from six new centers located in
Australia, Croatia, Spain, Switzerland, and United Kingdom.
The eligibility criteria were generally unchanged, but in ad-
dition, patients treated between 2013 and March 2016 were
allowed, as the outcome data were then mature enough to
reach 3 years of expected follow-up. Contributions of less than
one hundred patients were accepted for the validation set.
Data collection was limited to information regarding original
IGCCCGprognostic group, progression-free survival (PFS) and
overall survival (OS), treatment regimen as well as LDH and its
upper limit of normal (ULN).
End Points
Primary end points were PFS and OS. OS was defined as
the time from start of chemotherapy to death of any cause.
PFS was defined from start of chemotherapy to progression,
defined by radiologic progression, unequivocal tumor-
marker increase, or death, whichever came first. PFS
was used for the prognostic model training.
Statistical Methods
All patients with available PFS and/or OS information were
used to update the survival probabilities. Kaplan-Meier
estimates were used to update survival estimates accord-
ing to the original IGCCCG. 95% CIs are provided via log-log
transform.4,5 Median follow-up estimates for PFS were
obtained via the reverse Kaplan-Meier method.6
The prognostic model analysis set was formed of patients
with all candidate variables available. Candidate variables
were the pre-chemotherapy HCG as a continuous variable,
LDH levels 3 upper limit of normal reference range for the
laboratory (ULN), site of primary (mediastinum v gonadal or
retroperitoneal or other), age (in years), and presence of
lung metastases. The prognostic model was developed for
PFS and applied to both PFS and OS. Both end points were
administratively censored at a 3-year horizon to harmonize
duration of follow-up across data sources and since most
events occurred in this time frame.
Because of the limited number of intermediate prognosis
patients available, only the good prognostic group was














   Insufficient data
   Not meeting inclusion criteria






set with PFS information
(n = 1,238)
Available patients with




FIG 1. CONSORT diagram. OS, overall survival; PFS, progression-free survival.
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The prognostic model analysis was done via a variable im-
portance algorithm based on conditional survival forest. A
conditional survival forest is an ensemble of conditional survival
trees aggregated together to improve predictive performance.
Each tree is fitted on a random subset of the original analysis
set, and only a random subset of the candidate variables can
be selected at each binary partitioning. The variable impor-
tance of each candidate variable is its contribution to the final
prediction. The most relevant variables were used to further
split the original good prognostic group into subgroups. This
analysis was performed using the ranger R package.
The discrimination of the new subclassification was
assessed using time-dependent area under the receiving
curve (AUC) at 3 years.
Sensitivity Analyses
Not all patients were treated according to international
guidelines. To investigate the potential confounding effect
of treatment intensity, treatments given were classed into
two major clusters: 3 3 bleomycin, etoposide, cisplatin
(BEP) or 4 3 EP (or equivalent), and 4 3 BEP (or
equivalent). The model was applied to good prognostic
patients treated with 3 3 BEP or 4 3 EP (or equivalent) to
assess if model performance is affected by treatment.
All analyses were performed using SAS version 9.4 (Cary,
NC) and R software (version 3.6.0).
RESULTS
Patient Characteristics
In total, data on 13,684 patients with GCT were received, of
whom 12,179 (89%) were eligible. The reasons for ineli-
gibility are listed in Figure 1. Of these eligible patients,
2,451 patients had metastatic seminoma and were avail-
able for the calculation of OS probabilities. Among them,
2,077 patients were initially recorded in local or national
cohorts, whereas 374 came from clinical trial databases.
Because of inconsistent or missing progression data, only
2,402 out of 2,451 (98%) patients were used to update PFS
probabilities.
Disease progression occurred in 304 patients, and 140
patients died. The median follow-up for PFS was 6.1 years
(6.6 year for cohorts, 2.8 for trials) and 81% had been
followed for at least 3 years from start of chemotherapy
(87% for cohorts, 45% for trials). The median follow-up
among survivors was 5.9 years, and the said follow-up
ranged from 18 days to 26 years.
The prognostic model analysis set was restricted to 1,259
patients (1,197 good prognosis and 62 intermediate
prognosis) with all candidate variables available, of which
1,238 (1,176 good prognosis and 62 intermediate prog-
nosis) also had information on date of progression.
Appendix Table A1 (online only), shows the baseline
characteristics of the 2,451 patients overall and divided
between patients included or not included in the prognostic
model analysis set because of missing data, showing no
marked difference between them; however, more cohort
patients (92.7%) were excluded from the analysis set
compared with trial patients. The most common reason for
exclusion was incomplete information about LDH (70% of
excluded patients). PFS and OS Kaplan-Meier curves
confirm absence of selection bias (Appendix Fig A1, online
only).
Updated Outcomes by Original IGCCCG
The 5-year PFS probability was 89% (95% CI, 87 to 90) and
79% (95% CI, 70 to 85) in good and intermediate IGCCCG
prognostic groups, respectively (Fig 2A). The corresponding
figures in the 1997 publication were 82% and 67%.
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FIG 2. Survival probabilities and 95% CI according to original IGCCCG prognostic groups for (A) PFS and (B) OS. IGCCCG, International Germ-Cell
Cancer Collaborative Group; OS, overall survival; PFS, progression-free survival.
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The 5-year OS probability was 95% (95% CI, 94 to 96) and
88% (95% CI, 80 to 93) in good and intermediate prog-
nostic groups, respectively (Fig 2B). The corresponding
figures in the 1997 publication were 86% and 72%.
Formal statistical comparisons were not possible since the
CI were not reported in the original publication.
New Prognostic Factors
A total of 1,176 good prognosis patients with PFS infor-
mation were used for training. Appendix Figure A2 (online
only). shows the result of the variable importance algorithm.
LDH standardized by its ULN was identified as the single
most significant prognostic factor for PFS in good prognosis
patients. In addition, hCG appears to be weakly informative
to predict patient prognosis, but its relative importance is
marginal compared with LDH divided by UNL (25 times
less). No other variable appeared relevant (Data Supple-
ment, online only).
To select the optimal threshold for LDH/ULN, 20,000
conditional survival trees were fitted on randomly drawn
subset of the analysis set, and the threshold chosen was
collected for each tree. Thresholds of 23 and 2.53 ULN of
LDH were most often proposed by the conditional trees.
The threshold of 2.53 ULN was chosen because of its
higher specificity; 267 out of 1,197 good prognosis patients
(22.3%) had LDH above 2.53 ULN.
Figure 3A shows PFS and OS in the analysis set for this
classification. Good prognostic IGCCCG patients with LDH
above 2.53 ULN had worse survival probabilities than
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FIG 3. (A) PFS and (B) OS probabilities and 95% CI in the analysis set and (C, D) in the validation set by original International Germ-Cell Cancer
Collaborative Group prognostic group with subdivision of good risk by LDH level (# 2.5 ULN, . 2.5 ULN). LDH, lactate dehydrogenase; OS, overall
survival; PFS, progression-free survival; ULN, upper limit of normal.
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patients with LDH below or equal to 2.53ULN, as shown in
Table 1. Good prognosis patients with LDH above 2.53
ULN had a 3-year PFS of only 80% (95%CI, 75 to 84) and a
3-year OS of only 92% (95%CI, 88 to 95) versus 92% (95%
CI, 90 to 94) and 97% (95% CI, 96 to 98) in the group with
lower LDH. In particular, the survival probabilities of good
prognosis patients with an LDH above 2.53 ULN were
similar to the intermediate prognosis patients. This was true
for both end points, although the differences are less
striking for OS because of the low number of deaths ob-
served. In the analysis set, the time-dependent AUC at
3 years was 0.61.
Independent Validation
To validate LDH as a new prognostic factor, 764 patients
were independently collected. The set consisted of 554
additional patients treated between 1995 and 2016 at the
institutions contributing to the analysis set, and 210 pa-
tients treated between 1996 and 2016 from the six addi-
tional centers.
Overall, 114 out of 714 good prognosis patients (15.9%)
had an LDH above 2.53 ULN. As shown in Figure 3B and
Table 1, the difference in PFS observed between the two
subgroups of good prognosis patients is maintained, as well
as the discriminative ability, with a 3-year AUC of 0.64. This
difference seems to hold for OS as well, but this cannot be
tested owing to small number of events.
Sensitivity Analysis on Treatment Intensity
Table 2 shows the repartition of patients forming the
training and validation sets treated with 33 BEP or 43 EP
(or equivalent) versus 43 BEP (or equivalent). 43 BEP (or
equivalent) contains patients treated with 4 3 BEP, 4 3
vincristine, ifosfamide, cisplatin, 43 paclitaxel, bleomycin,
etoposide, cisplatin (TBEP), and carboplatin, bleomycin,
vincristine, cisplatin (CBOP)/BEP.
Figure 4 shows the PFS according to the new classification
among good prognosis patients who were treated according
to international guidelines, with 3 3 BEP or 4 3 EP. When
restricting to patients treated with 3 3 BEP or 4 3 EP, the
difference in PFS between low and high LDH in good
prognosis patients remained, in both the training set and
the validation set, excluding that the difference might be
because of different treatment approaches. The time-
dependent AUC at 3 years was 0.61 in the restricted
training set and 0.64 in the restricted validation set.
Similar findings were also observed for OS in the analysis
set; however, this was based on fewer events.
DISCUSSION
The international IGCCCG-Update Consortium database is
the largest source of information on metastatic GCT
worldwide. In this report, we analyzed the subset of 2,451
patients with metastatic seminoma treated between 1990
and 2013 with modern-type cisplatin- and etoposide-based





Good With LDH £ 2.53
ULN (n 5 930)
Good With LDH > 2.53
ULN (n 5 267)
Intermediate
(n 5 62)
Good With LDH £ 2.53
ULN (n 5 600)
Good With LDH > 2.53
ULN (n 5 114)
Intermediate
(n 5 50)
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
3 BEP or 4 EP (or
equivalent)
757 (81.4) 172 (64.4) 14 (22.6) 520 (86.7) 86 (75.4) 10 (20.0)
4 BEP (or equivalent) 166 (17.8) 91 (34.1) 47 (75.8) 60 (10.0) 24 (21.1) 25 (50.0)
Other 7 (0.8) 4 (1.5) 1 (1.6) 20 (3.3) 4 (3.5) 15 (30.0)
Abbreviations: BEP, bleomycin, etoposide, cisplatin; LDH, lactate dehydrogenase; ULN, upper limit of normal.



















Good with LDH # 2.53 ULN 92 (90 to 94) 71/916 (8) 97 (96 to 98) 28/930 (3) 93 (90 to 95) 44/600 (7) 99 (97 to 99) 8/600 (1)
Good with LDH . 2.53 ULN 80 (75 to 84) 53/260 (20) 92 (88 to 95) 24/267 (9) 75 (65 to 82) 28/114 (25) 96 (90 to 99) 4/114 (4)
Intermediate 78 (65 to 86) 14/62 (23) 93 (82 to 97) 7/62 (11) 61 (46 to 73) 19/50 (38) 80 (65 to 89) 9/50 (18)
Abbreviations: LDH, lactate dehydrogenase; OS, overall survival; PFS, progression-free survival; ULN, upper limit of normal.
6 © 2021 by American Society of Clinical Oncology
Beyer et al
Downloaded from ascopubs.org by University of Zurich on April 27, 2021 from 089.206.112.017
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
chemotherapy and validated our results in additional 764
patients.
Compared with the results of the original IGCCCG cohort,
which were based on data on only 660 patients with
seminoma, good prognosis as well as intermediate prog-
nosis metastatic seminoma in the IGCCCG-Update Con-
sortium database experienced substantially improved
survival. Previous smaller series in patients with GCT also
reported better results compared with the original IGCCCG
cohort.7-11 However, the IGCCCG database is multicenter,
international, and by far the largest collection for patients
with pure seminoma. Improvements may have resulted
from stage migration because of earlier diagnosis and
better diagnostic tools, improved supportive care, superi-
ority of cisplatin- and etoposide-based first-line treatment
over other conventional combinations, the use of upfront
dose-intensified regimens, more stringent use and higher
quality of post-chemotherapy management, better salvage
strategies in nonresponding or relapsing patients, more
stringent guideline adherence, centralization of care at
experienced expert centers, or a combination of these
factors. Given 5-year PFS and OS survival probabilities of
88% (95% CI, 87 to 89) and 95% (95% CI, 94 to 96),
respectively, across all prognostic groups, metastatic
seminoma represents the most curable metastatic cancer
in males.
An important finding of the present analysis is that the
original IGCCCG classification as published in 1997 still
correctly identifies two prognostic groups with significantly
different PFS and OS probabilities. However, we identified
LDH/ULN > 2.5
LDH/ULN ≤ 2.5
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FIG 4. Survival probabilities and 95%CI of good prognosis patients according to LDH levels in the analysis set for (A) PFS and (B) OS, as well as in
the (C, D) validation set, restricted to patients treated with three BEP or four EP. BEP, bleomycin, etoposide, cisplatin; LDH, lactate dehy-
drogenase; OS, overall survival; PFS, progression-free survival; ULN, upper limit of normal.
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LDH above 2.53 ULN levels before chemotherapy as an
additional adverse prognostic factor that allowed splitting
the good prognostic group further. Good prognosis patients
with an elevated LDH above 2.53 ULN before chemo-
therapy experienced significantly worse outcomes. This
finding confirms previous reports that suggested elevated
LDH as an adverse prognostic factor in metastatic semi-
noma, but in much smaller sample sizes.9,12-14 In the
original IGCCCG publication, LDH was also identified as an
adverse prognostic factor with a cutoff of 23 ULN, but was
not added to the final classification. However, in this
analysis, we suggest a cutoff of 2.53 ULN because of its
higher specificity.
Other variables such as age, extragonadal primary tumor,
elevated levels of hCG, or the presence of lung metas-
tases did not add significant prognostic information in
good prognosis patients once LDH elevations were
considered.
The majority of patients in the IGCCCG-Update Consortium
database were treated according to international guidelines
consisting of three cycles BEP or four cycles EP in good
prognosis patients and four cycles BEP or three cycles BEP
plus one cycle EP in intermediate prognosis patients. In-
terestingly, in both the training and validation sets, patients
with elevated LDH were more often treated with four cycles
of BEP or equivalent, compared with good patients with low
LDH (34.1% v 17.8% in analysis set, and 21.1% v 10% in
validation set). Possibly, based on the reports mentioned,
some experts had already stepped away from international
guidelines and intensified treatment for good prognosis
patients with elevated LDH.
However, because of its retrospective nature, our analysis
cannot inform which treatment strategy is best in any of the
described subsets. Until the availability of prospective trials
results, our analysis does not allow to recommend, for
example, using four instead of three cycles BEP in good
(according to the original classification) prognosis patients
who have an LDH level above 2.53 ULN. Additionally,
despite the large international effort, the sample size of
intermediate prognosis seminoma in the IGCCCG-Update
Consortium database was too small to study any additional
prognostic factors.
Because of these limitations, the original IGCCCG
classification as published in 1997 remains the refer-
ence for treatment decisions in daily practice as all
currently available trials used the original IGCCCG
classification for treatment stratification. However, re-
finement of the original IGCCCG classification by adding
LDH as an adverse prognostic factor within the good
prognostic group allows for a better assessment of in-
dividual patients and can help to shape future treatment
strategies in metastatic seminoma. Knowledge about the
prognostic impact of LDH supports the development of
trials with de-escalation strategies in good prognosis
seminoma with low LDH to further reduce treatment
burden in patients likely to be cured. By contrast, inferior
outcomes despite modern-type cisplatin- and etoposide-
based chemotherapy in good prognosis seminoma with
elevated LDH as well as in intermediate prognosis
seminoma underscore the need to re-evaluate and im-
prove current treatment strategies in such patients in
prospective clinical trials.
In conclusion, we confirm that the original IGCCCG clas-
sification retains its relevance in metastatic seminoma, but
with clearly improved outcomes. The classification can be
further refined by adding LDH at a cutoff of 2.53 ULN as
an additional adverse prognostic factor within the good
prognosis group.
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TABLE A1. Baseline Characteristics of Patients Included in or Excluded From the Analysis Set
Baseline Characteristics
Analysis Set Total (N 5 2,451)
Patients Excluded From Analysis Set
(n 5 1,192)
Patients in Analysis Set
(n 5 1,259) No. (%)
Age at diagnosis of metastatic disease, years
Median 39 37 38
Range 17-75 16-77 16-77
Q1-Q3 32-46 32-43 32-44
N obs 989 1,259 2,248
IGCCCG risk group
Good 1,132 (95.0) 1,197 (95.1) 2,329 (95.0)
Intermediate 60 (5.0) 62 (4.9) 122 (5.0)
Progression-free survival status
No progression 1,014 (85.1) 1,084 (86.1) 2,098 (85.6)
Progression in the first 3 years 119 (10.0) 132 (10.5) 251 (10.2)
Progression after 3 years 31 (2.6) 22 (1.7) 53 (2.2)
Missing 28 (2.3) 21 (1.7) 49 (2.0)
Overall survival status
Alive 1,124 (94.3) 1,187 (94.3) 2,311 (94.3)
Death in the first 3 years 36 (3.0) 48 (3.8) 84 (3.4)
Death after 3 years 32 (2.7) 24 (1.9) 56 (2.3)
Location of primary tumor
Gonadal 733 (61.5) 1,136 (90.2) 1,869 (76.3)
Retroperitoneal 60 (5.0) 76 (6.1) 136 (5.6)
Mediastinal 23 (1.9) 47 (3.7) 70 (2.9)
Other 54 (4.5) 0 (0.0) 54 (2.2)
Missing 322 (27.0) 0 (0.0) 322 (13.1)
Presence of lung metastases
No 954 (80.0) 1,179 (93.6) 2,133 (87.0)
Yes 72 (6.0) 80 (6.4) 152 (6.2)
Missing 166 (13.9) 0 (0.0) 166 (6.8)
Pre-chemo HCG levels (U/L)
Median 3.0 4.0 3.3
Range 0.0-26,921.0 0.0-1,285,000.0 0.0-1,285,000.0
Q1-Q3 1.0-17.4 1.0-16.0 1.0-17.0
N obs 716 1,259 1,975
Pre-chemo HCG levels (categorised)
, 5,000 IU/L 708 (59.4) 1,234 (98.0) 1,942 (79.2)
5,000 IU/L-50,000 IU/L 8 (0.7) 17 (1.4) 25 (1.0)
. 50,000 IU/L 0 (0.0) 8 (0.6) 8 (0.3)
Missing 476 (39.9) 0 (0.0) 476 (19.4)
Pre-chemo LDH/ULN
LDH/ULN # 2.5 266 (22.3) 968 (76.9) 1,234 (50.3)
LDH/ULN . 2.5 87 (7.3) 291 (23.1) 378 (15.4)
Missing 839 (70.4) 0 (0.0) 839 (34.2)
(continued on following page)
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TABLE A1. Baseline Characteristics of Patients Included in or Excluded From the Analysis Set (continued)
Baseline Characteristics
Analysis Set Total (N 5 2,451)
Patients Excluded From Analysis Set
(n 5 1,192)
Patients in Analysis Set
(n 5 1,259) No. (%)
Prognostic groups
Good with LDH # 2.5 ULN 260 (21.8) 930 (73.9) 1,190 (48.6)
Good with LDH . 2.5 ULN 77 (6.5) 267 (21.2) 344 (14.0)
Intermediate 60 (5.0) 62 (4.9) 122 (5.0)
Missing 795 (66.7) 0 (0.0) 795 (32.4)
Conventional treatment
3 3 BEP 416 (34.9) 594 (47.2) 1,010 (41.2)
3 3 EP or more 442 (37.1) 349 (27.7) 791 (32.3)
4 3 BEP or more 294 (24.7) 265 (21.0) 559 (22.8)
3 3 VIP or more 15 (1.3) 27 (2.1) 42 (1.7)
3 3 TBEP or more 2 (0.2) 10 (0.8) 12 (0.5)
BEP plus VIP and/or TIP (minimum three cycles total) 2 (0.2) 1 (0.1) 3 (0.1)
BEP plus EP (minimum three cycles total) 20 (1.7) 11 (0.9) 31 (1.3)
CBOP/BEP 1 (0.1) 2 (0.2) 3 (0.1)
Year of treatment
, 1995 140 (11.7) 23 (1.8) 163 (6.7)
1995-1999 217 (18.2) 245 (19.5) 462 (18.8)
2000-2004 260 (21.8) 291 (23.1) 551 (22.5)
2005-2009 321 (26.9) 412 (32.7) 733 (29.9)
2010-2013 254 (21.3) 288 (22.9) 542 (22.1)
Type of study
Trial 87 (7.3) 287 (22.8) 374 (15.3)
Cohort 1,105 (92.7) 972 (77.2) 2,077 (84.7)
Abbreviations: BEP, bleomycin, etoposide, cisplatin; CBOP, carboplatin, bleomycin, vincristine, cisplatin; EP, etoposide, cisplatin; HCG, human chorionic
gonadotropin; IGCCCG, International Germ-Cell Cancer Collaborative Group; LDH, lactate dehydrogenase; TBEP, paclitaxel, bleomycin, etoposide, cisplatin;
TIP, paclitaxel, ifosfamide, cisplatin; ULN, upper limit of normal; VIP, vincristine, ifosfamide, cisplatin.
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FIG A2. Variable importance of all candidate variables on PFS in the
prognostic model analysis set. HCG, human chorionic gonadotro-
pin; LDH, lactate dehydrogenase; ULN, upper limit of normal.
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